Home > Boards > US Listed > Biotechs > Aurinia Pharmaceuticals Inc (AUPH)

AUPH Forget all the noise, just concentrate on this:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
lidopete Member Profile
 
Followed By 0
Posts 552
Boards Moderated 0
Alias Born 07/16/06
160x600 placeholder
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021 Business Wire - 10/27/2021 7:07:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/26/2021 4:34:01 PM
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021 Business Wire - 10/26/2021 4:10:00 PM
Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest Dow Jones News - 10/25/2021 9:25:00 AM
EDIT, AUPH and DWAC among after hours Seeking Alpha - 10/22/2021 5:21:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/22/2021 4:31:38 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 9/17/2021 4:04:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2021 5:02:32 PM
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire - 9/15/2021 1:11:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 6:17:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:12:58 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/14/2021 5:11:39 PM
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Business Wire - 9/10/2021 1:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2021 4:05:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/8/2021 4:04:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/27/2021 4:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/26/2021 4:16:49 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/17/2021 4:07:54 PM
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases Business Wire - 8/17/2021 6:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/10/2021 4:09:58 PM
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference Business Wire - 8/9/2021 7:55:00 AM
SCWorx, Aurinia Pharmaceuticals leads healthcare gainers; Dicerna Pharmaceuticals, iCAD among major losers Seeking Alpha - 8/6/2021 11:02:32 AM
Aurinia Pharma extends gains following robust Q2 top-line growth Seeking Alpha - 8/6/2021 6:08:45 AM
Aurinia Pharma EPS misses by $0.01, beats on revenue Seeking Alpha - 8/5/2021 4:16:06 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/5/2021 4:14:46 PM
lidopete   Thursday, 12/17/20 10:42:00 PM
Re: None
Post # of 13870 
AUPH Forget all the noise, just concentrate on this:

Cowen calls Aurinia a best idea for 2021 into FDA action date Aurinia Pharmaceuticals is positioned for a "meaningful inflection" into the January 22 FDA action date for voclosporin in lupus nephritis, Cowen analyst Ken Cacciatore tells investors in a research note. Citing Voclosporin's efficacy and safety, combined with clinician enthusiasm and an unmet clinical need, the analyst has "strong conviction" that voclosporin should be "rapidly incorporated" into the standard of care and has $1B-plus sales potential. He calls Aurinia a best for 2021 and recommends adding to positions at current levels. Cacciatore keeps an Outperform rating on the shares with a $30 price target.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences